Skip to NavigationSkip to content

News

0
China’s food and drug regulator recently carried out a one year long review of clinical trials and the resultant data, finding that the 80% of data...
0
The drug has received a final recommendation from NICE for the treatment of visual impairment due to macular oedema secondary to branch retinal vein...
0
The London-based company has released more positive data from a Phase III trial for Epidiolex. The experimental cannabidiol drug has been used to...
0
According to research and consulting firm GlobalData, the Malaysian market is projected to go from $2.3 billion in 2015 to $3.6 billion by 2020 with...

Features

Paul Ranson, of global law firm Morgan Lewis' London Life Sciences Practice examines how UK biopharma must now adapt to a changing landscape